Angela Labrozzi, channel partner director, Within3, outlines how an asynchronous clinical trials model can help pharma and healthcare companies lower emissions, save money, and maximise time.
Key insights:
- As China and India produce the majority of the worlds APIs which can cause supply chain disruption when combined with climate change.
- A decentralised approach to various aspects of clinical trials can also amplify collaboration as it reduces the environmental impact of in-person participation.
- If pharma companies adopt a virtual and asynchronous approach to more trial-related activities, they can proactively reduce total carbon emissions.
Today, the global pharmaceutical industry accounts for 4.4% of global greenhouse gas emissions. For every $1 million the sector made in 2015, it generated 48.55 tonnes of CO2. In the battle to curb global warming and the devastating effects it will ultimately have on people and the planet, the industry must strive to reduce emissions.